SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690) (LRMR) — Aug 31, 2020

Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690)
Date: Aug. 31, 2020 · CIK: 0001374690 · Accession: 0001193125-20-236337

AI Filing Summary & Sentiment

File numbers found in text: 333-246370

Date
August 31, 2020
Author
Not clearly detected
Form
CORRESP
Company
Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690)

Letter

Larimar Therapeutics, Inc.

Three Bala Plaza East, Suite 506

Bala Cynwyd, Pennsylvania 19004

August 31, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-7553

Re: Larimar Therapeutics, Inc.

Registration Statement on Form S-3

Filed August 14, 2020 (File No. 333-246370)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-246370) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:01 PM, Eastern Time, on September 1, 2020, or as soon thereafter as is practicable.

Please contact Rachael M. Bushey, Esq. of Troutman Pepper Hamilton Sanders LLP, counsel to the Company, at (215) 981-4331 to provide notice of effectiveness, or if you have any questions or comments concerning this request.

[Remainder of the page intentionally left blank]

Very truly yours,
LARIMAR THERAPEUTICS, INC.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 Larimar Therapeutics, Inc.

Three Bala Plaza East, Suite 506

Bala Cynwyd, Pennsylvania 19004

August 31, 2020

 VIA EDGAR

U.S. Securities and Exchange Commission

 Division of Corporation
Finance

 100 F Street, N.E.

 Washington, D.C. 20549-7553

Re:
 Larimar Therapeutics, Inc.

 Registration Statement on Form S-3

 Filed August 14, 2020 (File No. 333-246370)

 Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the
“Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-246370) (the
“Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:01 PM, Eastern Time, on September 1, 2020, or as soon thereafter as is practicable.

Please contact Rachael M. Bushey, Esq. of Troutman Pepper Hamilton Sanders LLP, counsel to the Company, at (215) 981-4331 to provide notice of effectiveness, or if you have any questions or comments concerning this request.

 [Remainder of the page intentionally left blank]

Very truly yours,

 LARIMAR THERAPEUTICS, INC.

 By:

 /s/ Carole Ben-Maimon

Name:

Carole Ben-Maimon, M.D.

Title:

President and Chief Executive Officer